CUBT 株価分析 — Curative Biotechnology Inc (Healthcare >> Biotechnology)
CUBT に関するよくある質問
CUBTのROE(自己資本利益率)は?
Curative Biotechnology IncのROEは33.87%です。
CUBTの配当利回りは?
Curative Biotechnology Incの配当利回りは0.00%です。
CUBTの品質スコア(Quality Score)は?
当社のAIはCUBTの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CUBTは今が買い時ですか?
当社AIのタイミングスコアは100点中3点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CUBTはどのセクターに属しますか?
Curative Biotechnology IncはHealthcare >> Biotechnologyセクターに分類されます(NYSE MKT市場)
CUBT AI Analysis Summary
Our AI summary for CUBT: Curative Biotechnology Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 33.87%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.30
Price
0.27
(25.73%)
Day Change
|
|
|---|
CUBT, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.30 |
| PBV / Sector |
-1.60 / 44,105.10
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
711.886175000000
|
| Average 1W Daily Value |
1197.662400000000
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:50 |
| Symbol | CUBT |
| Name | CURATIVE BIOTECHNOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 7.66 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10.07 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410
Phone: 561 907 8990
Website: https://curativebiotech.com
Sector: Healthcare >> Biotechnology
Description: Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google